Surrozen, Inc./DE Increase (Decrease) in Accounts Receivable, Related Parties
Surrozen, Inc./DE (SRZN) reported Increase (Decrease) in Accounts Receivable, Related Parties of -$208.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2026-08-06
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for the quarter ending 2026-06-30 was $0.00.
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for the quarter ending 2026-03-31 was -$208.00K.
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for the quarter ending 2025-12-31 was -$43.00K, a 108.57% decline year-over-year.
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for the quarter ending 2025-09-30 was -$1.00K.
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for fiscal 2025 was -$294.00K, a 158.57% decline from fiscal 2024.
- Surrozen, Inc./DE increase (decrease) in accounts receivable, related parties for fiscal 2024 was $502.00K.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$208.00K 10-Q · filed 2026-08-06 | -$251.00K derived: sum of 3 quarters · filed 2026-08-06 | -$252.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$208.00K 10-Q · filed 2026-05-06 | -$251.00K derived: sum of 2 quarters · filed 2026-05-06 | -$252.00K derived: sum of 3 quarters · filed 2026-05-06 | -$502.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$44.00K derived: sum of 2 quarters · filed 2026-03-23 | -$294.00K derived: sum of 3 quarters · filed 2026-08-06 | -$294.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$251.00K derived: sum of 2 quarters · filed 2026-08-06 | -$251.00K 10-Q · filed 2025-11-07 | $251.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$250.00K 10-Q · filed 2026-08-06 | $252.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $502.00K derived: sum of 2 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $502.00K 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |